NASH Treatment Market Accelerates as Rezdiffra and Wegovy Establish Fibrosis-Defined Drug Pathways, Says Strategic Market Research

The Global non-alcoholic steatohepatitis (NASH/MASH) treatment market is projected to jump from $8.75B in 2025 to $46.87B by 2032 (27.1% CAGR), driven by first dedicated drug approvals and clearer payer-defined eligibility tied to F2–F3 fibrosis. Rezdiffra (FDA-approved March 2024) and Wegovy (FDA-approved Aug 2025) extend treatment pathways beyond broad fatty-liver prevalence, emphasizing fibrosis confirmation, noninvasive staging, and specialist referral workflows. Growth is expected to be payer- and diagnosis-capacity constrained in the near term, but late-stage pipeline expansion could broaden the “treatment ladder” and support additional mechanisms beyond GLP-1.

Analysis

The investable issue is not disease prevalence; it is conversion of a huge screened population into reimbursed prescriptions. That makes workflow-enabled players the clearest beneficiaries: NVO can use its obesity/diabetes prescriber base to lower customer-acquisition cost and slot MASH into an existing commercial engine, while MDGL is more dependent on specialist bottlenecks that can keep early revenue well below the market’s long-duration TAM models. In other words, the first dollars should accrue to companies that already sit inside cardiometabolic care, not to pure hepatology franchises.

Competition is likely to segment rather than consolidate. GLP-1s should own the broad, overweight/diabetic MASH cohort because they improve multiple metabolic endpoints at once, while liver-directed agents become the niche answer for fibrosis-heavy patients, non-obese patients, and combination regimens. That argues for a narrower peak-sales path for MDGL and a higher probability that AKRO/IVA become “proof-of-value” names rather than immediate commercial winners unless they show additive fibrosis benefit on top of incretins.

The near-term risk is that payer friction and low diagnosis rates cap scripts for 1-2 quarters, causing multiple compression even if the long-term thesis is intact. The reversal trigger is not another market-size slide deck; it is evidence that noninvasive staging and prior-auth pathways are scaling fast enough to lift treated patients from single-digit penetration to something durable. If that does not happen, the stock reaction to the theme is likely ahead of fundamentals rather than ahead of revenue.

Key Decisions for Investors

• Long NVO on pullbacks vs the obesity/GLP-1 complex, 3-12 month horizon: best risk/reward because MASH adds incremental indication value to an already proven distribution machine; thesis breaks if obesity prescribing decelerates or MASH access disappoints.
• Pair trade: long NVO / short MDGL for a relative-value expression of distribution advantage over hepatology-only commercialization, with 1-3 month catalyst window around payer coverage and prescription data; cover the short if MDGL shows accelerating refill persistence or broader reimbursement.
• Small tactical long AKRO or IVA via call spreads into Phase 3 updates only if sizing is capped, since the upside is binary and depends on whether these programs can show additive fibrosis benefit versus incretin backbones; invalidated by weak interim efficacy or tolerability.
• Set a watch item on MASH diagnosis and prior-authorization metrics rather than the TAM print: if fibrosis-confirmed patient flow does not inflect over the next 1-2 quarters, fade any rally in the basket because commercial conversion will lag the market narrative.